Trial Profile
A Pilot Study to Determine if Intravitreal Injections of Pegaptanib Sodium (Macugen) Given Every 12 Weeks for a Year After an Induction Phase of Three Injections Every 6 Weeks Will Reduce the Progression of Proliferative Diabetic Retinopathy in Patients Without Significant Vitreous Hemorrhage in Comparison to Treatment With Retinal Photocoagulation Alone and After an Induction Phase
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Pegaptanib (Primary)
- Indications Diabetic retinopathy
- Focus Therapeutic Use
- Acronyms M-PDRS ED
- 09 Dec 2011 New trial record